Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

10 Jan 2013 07:00

RNS Number : 2152V
Instem plc
10 January 2013
 



10 January 2013

Embargoed for 07:00

 

Instem plc

("Instem", the "Company" or the "Group")

 

Trading Update

 

Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, is pleased to announce that following the successful conclusion of several contract negotiations it expects results for the year ended 31 December 2012 to be in-line with market forecasts.

 

License income was second-half weighted as in previous years and, while first half revenue was marginally below that of the comparable period in 2011, the Group expects to report revenue and profit for 2012 in line with forecasts, due to a high number of contracts being signed during the final quarter of the year.

 

The contracts signed in December 2012 were with some of the world's most notable businesses in the pharmaceutical and research industries, including, among others, a top 10 global Biopharmaceutical company, several of the world's leading preclinical Contract Research Organisations and JOINN, China's largest provider of pre-clinical studies.

 

Instem's balance sheet remains strong with net cash of approximately £2.2m at 31 December 2012 (31 December 2011: £2.9m). Due to a number of significant contracts falling in the final quarter of the year, the related cash inflow is now expected in the first quarter of 2013.

 

Phil Reason, CEO of Instem plc, commented: "We are delighted to have signed such high calibre contracts in the final quarter of 2012. It was especially pleasing that these contracts were representative of the breadth of our innovative product set in its entirety, including purchases of Provantis and Centrus alongside our Standard for Exchange of Nonclinical Data (SEND) module and our newly launched Logbook solution.

 

"Underlying demand for Instem solutions remains strong, despite uncertainty remaining in the pharmaceutical market due to structural changes. In the medium term, we expect these changes in the market to drive the requirement for operational efficiencies which our software facilitates. Therefore with our extensive customer base, broad product set and market leading position, we view the future with confidence."

 

Notice of Results

The Company expects to report its results for the year ended 31 December 2012 on 27 March 2013.

 

For further information, please contact:

 

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO

Nigel Goldsmith, CFO

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Aubrey Powell

Joe Stroud

Newgate Threadneedle

+44 (0) 20 7653 9850

Caroline Evans-Jones

Fiona Conroy

 

About Instem plc

 

Instem is a leading supplier of IT solutions to the early development healthcare market. Instem's pre-clinical study management solutions accelerate drug and chemical development by increasing productivity, automating processes and enhancing practices that lead to safer and more effective drugs.

 

Instem has over 130 customers in North America, Europe, China, India and Japan, including 16 of the top 20 pharmaceutical and biotech companies such as GlaxoSmithKline and AstraZeneca. The Group employs over 110 people in seven offices in the US, UK, China and India; and has a full service distributor in Japan. It is estimated that approximately half of the world's pre-clinical drug safety data has been collected over the last 20 years via Instem software, making Instem an ideal partner to help unlock the scientific/commercial value from these legacy repositories.

 

To learn more about Instem please visit the Company's website, www.instem.com, or its investor centre http://investors.instem.com/

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLLFVDLRIAIIV
Date   Source Headline
29th May 20137:00 amRNSGlobal R&D Organisation selects Centrus & SRS
23rd May 20133:08 pmRNSResult of AGM
13th May 20137:00 amRNSAcquisition of Logos Technologies
26th Apr 20134:48 pmRNSPosting of Annual Report, Notice of AGM
23rd Apr 20136:20 pmRNSHolding(s) in Company
18th Apr 20137:00 amRNSCustomer Wins for New Provantis Release
27th Mar 20137:00 amRNSFinal Results
12th Mar 20137:00 amRNSNotice of Final Results
1st Mar 20133:25 pmRNSHolding(s) in Company
28th Feb 20137:00 amRNSUS Government Contract Win
30th Jan 20139:42 amRNSHolding(s) in Company
21st Jan 20137:00 amRNSHolding(s) in Company
10th Jan 20137:01 amRNSJOINN Laboratories China Purchases Provantis
10th Jan 20137:00 amRNSTrading Update
24th Dec 20127:00 amRNSTrading Update
18th Dec 20127:00 amRNSMulti-year Contract Extension & New Awards
3rd Dec 20127:00 amRNSCentrus Contract Win
7th Nov 20127:00 amRNSContract Win with US Government Research Agency
29th Oct 20127:00 amRNSChange of name of Nominated Adviser and Broker
19th Sep 20127:00 amRNSUnaudited Interim Results
5th Sep 20127:00 amRNSNotice of Interim Results
26th Jul 20127:00 amRNSTrading Update
25th Jul 20125:40 pmRNSHolding(s) in Company
22nd May 20123:46 pmRNSResult of AGM
8th May 201212:11 pmRNSPosting of Annual Report, Notice of AGM
24th Apr 20129:17 amRNSHolding(s) in Company
30th Mar 20124:52 pmRNSTotal Voting Rights and Capital
29th Mar 20122:49 pmRNSHolding(s) in Company
28th Mar 20127:00 amRNSFinal Results
26th Mar 20127:00 amRNSEstablishment of Instem India
8th Mar 20127:00 amRNSIssue of Equity and Director/PDMR Shareholding
20th Feb 20127:00 amRNSNotice of Final Results
9th Feb 20128:34 amRNSDirector/PDMR Shareholding
1st Feb 20129:14 amRNSAppointment of Nominated Adviser and Broker
18th Jan 20126:21 pmRNSChange of Name
9th Jan 20127:00 amRNSTrading Update
30th Nov 20113:57 pmRNSAppointment of CFO
21st Sep 20117:00 amRNSUnaudited Interim Results
10th Aug 20112:57 pmRNSNotification of Death of Director
4th May 20115:32 pmRNSPosting of Annual Report & Notice of AGM
22nd Mar 20117:00 amRNSFinal Results
4th Mar 20117:00 amRNSAcquisition of BioWisdom
19th Jan 20117:00 amRNSTrading Update
29th Oct 201011:34 amRNSTotal Voting Rights
19th Oct 20107:00 amRNSHolding(s) in Company
15th Oct 201010:38 amRNSHolding(s) in Company
13th Oct 20107:00 amRNSFirst Day of Dealings on AIM
19th Feb 20083:38 pmRNSDividend Declaration
15th Feb 200811:34 amRNSResults of GM
31st Jan 20083:28 pmRNSNotification of Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.